Collection of Biostatistics Research Archive
COBRA Preprint Series
Year 

Paper 

Minimum Description Length and Empirical
Bayes Methods of Identifying SNPs
Associated with Disease
Ye Yang∗

∗

David R. Bickel†

Ottawa Institute of Systems Biology, Department of Biochemistry, Microbiology, and Immunology
†
Ottawa Institute of Systems Biology, Department of Biochemistry, Microbiology, and Immunology, Department of Mathematics and Statistics, dbickel@uottawa.ca
This working paper is hosted by The Berkeley Electronic Press (bepress) and may not be commercially reproduced without the permission of the copyright holder.
http://biostats.bepress.com/cobra/art74
Copyright c 2010 by the authors.

Minimum Description Length and Empirical
Bayes Methods of Identifying SNPs
Associated with Disease
Ye Yang and David R. Bickel

Abstract

The goal of determining which of hundreds of thousands of SNPs are associated with disease poses one of the most challenging multiple testing problems.
Using the empirical Bayes approach, the local false discovery rate (LFDR) estimated using popular semiparametric models has enjoyed success in simultaneous
inference. However, the estimated LFDR can be biased because the semiparametric approach tends to overestimate the proportion of the non-associated single
nucleotide polymorphisms (SNPs). One of the negative consequences is that, like
conventional p-values, such LFDR estimates cannot quantify the amount of information in the data that favors the null hypothesis of no disease-association.
We address this problem of the semiparametric approach by proposing two simple
parametric methods under the minimum description length (MDL) and empirical
Bayes frameworks. The performances of the estimators corresponding to the two
proposed parametric models and of the popular semiparametric model are compared by simulation to select a method for analyzing genome-wide association
data.
The application of the coronary artery disease data indicates that the semiparametric method sometimes leads to overfitting due to nonparametric density estimation. Unlike semiparametric methods, the analyses based on the two parametric
models can measure the amount of information in the data that favors one hypothesis over another. In multiple simulation studies, the estimators associated with
the parametric mixture model consistently performs better than those of the other
two models.
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Abstract
The goal of determining which of hundreds of thousands of SNPs are associated
with disease poses one of the most challenging multiple testing problems. Using the
empirical Bayes approach, the local false discovery rate (LFDR) estimated using popular semiparametric models has enjoyed success in simultaneous inference. However,
the estimated LFDR can be biased because the semiparametric approach tends to
overestimate the proportion of the non-associated single nucleotide polymorphisms
(SNPs). One of the negative consequences is that, like conventional p-values, such
LFDR estimates cannot quantify the amount of information in the data that favors
the null hypothesis of no disease-association.
We address this problem of the semiparametric approach by proposing two simple
parametric methods under the minimum description length (MDL) and empirical
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Bayes frameworks. The performances of the estimators corresponding to the two
proposed parametric models and of the popular semiparametric model are compared
by simulation to select a method for analyzing genome-wide association data.
The application of the coronary artery disease data (Wellcome Trust Case Control Consortium, 2007) indicates that the semiparametric method sometimes leads to
overfitting due to nonparametric density estimation. Unlike semiparametric methods,
the analyses based on the two parametric models can measure the amount of information in the data that favors one hypothesis over another. In multiple simulation
studies, the estimators associated with the parametric mixture model consistently
performs better than those of the other two models.

1

Introduction

Genome-wide association studies employ either case-control designs or larger cohort designs. Both study designs aim to determine which SNPs are associated with the presence or
absence of disease. The most common measure of association is the odds ratio. Each allele
(or combination of alleles in the dominant and recessive models) of a SNP is associated
with the odds of disease; the odds ratio between two alleles is the odds of disease of one
allele divided by the odds of disease of the other allele. See Hirschhorn and Daly (2005)
for an informative review.
Two recent developments have made genome-wide association studies feasible. First,
genotyping has become more accurate and more affordable. Second, markers can now be
selected on the basis of linkage disequilibrium patterns observed across the human genome
(International HapMap Consortium, 2005). By identifying SNPs associated with disease,
genome-wide association studies can potentially lead to novel treatments and better disease
diagnosis and prevention (Wellcome Trust Case Control Consortium, 2007).
2
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In genome-wide association studies, different samples of individuals may be genotyped
for different reasons. For example, some studies are conducted in stages, beginning with
one or more screening stages of a high number of markers to select loci for a validation
stage of a much smaller number of markers over a possibly larger patient group (e.g. Göing
et al. (2001); McPherson et al. (2007)). The validation stage requires selecting markers as
having more evidence of association than was possible at the screening stage. The regions
of such loci may then be sequenced to identify genes that may causally influence the onset
of the disease or other trait. Alternatively, loci may be selected for potential clinical use
as disease risk factors in prognosis. Regardless of whether a data set is used to scan for
associations to be validated at a later stage, to validate hypothesized associations, or to
perform both functions simultaneously, its analysis will involve the selection of some SNPs
for their putative association with the disease.
Most commonly, p-values reported to quantify evidence for disease association are adjusted to control a family-wise error rate (e.g. Montana (2006); He et al. (2006)). This
practice, however, tends to be too conservative to identify many SNPs associated with
disease that have small odds ratios. Approaches with more statistical power include those
estimating a global false discovery rate (GFDR) (e.g. Sabatti et al. (2003)) and Bayesian
methods (e.g. Wacholder et al. (2004); Wellcome Trust Case Control Consortium (2007)).
Empirical Bayes approaches, including local false discovery rate (LFDR) estimation, have
the advantage of the full Bayesian approach that they can specify a posterior probability that a particular SNP is associated with disease but without depending on a prior
distribution specified before observing the data.
LFDR estimation does not suffer from the main two criticisms of standard p-value
approaches with regard to how the issue of multiple comparisons is handled: high falsenegative rates and difficulties of interpretation. First, standard p-value adjustments for
multiple comparisons incur an unacceptable loss of power due to an attempt to control the
3
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proportion of false positives among all tests. Such traditional correction of p-values for
multiple comparisons is not appropriate for the large number of tests needed for genomewide association (GWA) data sets since they have hundreds of thousands of SNPs. As
a test-wise version of the GFDR, the expected number of false positives among all statistically significant results, the estimated LFDR of each SNP’s association with disease
can rigorously account for multiple comparisons without that loss of power. The second
criticism of p-value approaches also applies to the control of the GFDR as an alternative
method for addressing the multiple-comparisons problem. That alternative requires the
selection of an arbitrary threshold, not allowing assignments of different levels of confidence
for significance to different tests (Ziegler et al., 2008). The standard response to this criticism is to compute the q-value, the minimum false discovery rate threshold at which each
null hypothesis would be rejected (Storey, 2002). However, the q-value can be difficult to
interpret since it does not approximate the probability that the hypothesis is true (Bukszár
et al., 2009). Unlike the p-value and q-value, the LFDR estimate is easily interpreted as an
approximate posterior probability that the null hypothesis is true (Greenwood et al., 2007;
Bukszár et al., 2009), provided that the estimate is not essentially 0% or 100% (Bickel,
2010a). At the same time, estimation of the LFDR is built on standard principles of frequentist inference, not relying on the choice of subjective or default prior distributions, as
in the purer Bayesian approaches that Wakefield (2007) and Wei et al. (2010) applied to
GWA data.
The estimation of LFDR and GFDR is normally performed using a discrete mixture
model, whether parametric (e.g., Allison et al. (2002); Pounds and Morris (2003); Pan
et al. (2003); Liao et al. (2004); Muralidharan (2010)) or semiparametric (e.g., Efron et al.
(2001); Efron (2004, 2007a)). The main application of semiparametric LFDR estimation
has been to microarray gene expression data (e.g., Efron et al. (2001); Efron (2004, 2007a);
Aubert et al. (2004)). In contrast with the large number of applications to microarray data
4
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analyses, only a few papers have applied LFDR estimation to GWA data (e.g., Greenwood
et al. (2007)). The estimated LFDR using the semiparametric approach is designed to be
conservative, leading to the bias that Pawitan et al. (2005) addressed by fitting a parametric
model to gene expression data. The parametric model has the additional advantage that
it can quantify the strength of the statistical evidence under the likelihood paradigm, as
explained below.
According to the likelihood framework, the likelihood ratio measures the degree to
which the data supports one hypothesized distribution over another (Blume, 2002; Hacking,
1965; Edwards, 1969; Royall, 1997). As a ratio of probability densities, the likelihood ratio
requires a single density associated with the alternative hypothesis and a single density
associated with the null hypothesis. Since, however, the alternative hypothesis typically
corresponds to an infinite number of probability density functions, a single density function
must be selected for the numerator of the likelihood ratio. While the principle of inference
to the best explanation suggests maximizing the alternative density over the parameter
space (Bickel, 2010d), that approach leads to overfitting from a predictive standpoint
since the density function selected depends on the same data as the likelihood. The full
Bayesian solution is to assign priors in order to integrate the likelihoods associated with
each hypothesis (Wei et al., 2010). Without requiring any prior distribution, the minimum
description length (MDL) principle also prevents overfitting by requiring that the density
function not depend on the data (Grünwald, 2007).
In Section 2, we will apply two parametric mixture models that approximate MDL
densities (Bickel, 2010b) to the problem of assessing the strength of evidence for association
with disease. We will also apply the same models and a semiparametric model of Efron
(2004) to LFDR estimation. Section 3 describes our application of those models to coronary
artery disease data (Wellcome Trust Case Control Consortium, 2007). In Section 4, we
report the relative performance of each of the estimators associated with the three models.
5
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Finally, we conclude the paper in Section 5 with recommendations for the analysis of GWA
data.

2

Methods

2.1

Model assumed as true

To investigate the association between the disease state and the ith SNP, logistic regression
estimates the ith SNP effect βi , the logarithm of the odds ratio for the ith SNP, where
i = 1, . . . , N, and N is the total number of the measured SNPs. For the ith SNP, we
perform the Wald test with βi = 0 as the null hypothesis and with βi 6= 0 as the alternative

 
d βbi , where βbi is the maximum
hypothesis. The Wald test statistic is Ti = βbi2 / Var
 
d βbi is the standard estimate of the variance of βbi
likelihood estimator of βi and Var
(Hosmer and Lemeshow, 2000).
Let gδ denote the probability density function admitted by the noncentral χ2 distribution of one degree of freedom and of a noncentrality parameter value δ. For all i = 1, . . . , N ,
according to Shieh (2005), the Wald test statistic Ti is approximately distributed according
to the probability density function gδi with noncentrality parameter
 
δi = βi2 /Var βbi ,

(1)

 
where Var βbi is the variance of βbi . The equation indicates that the value of δi is determined by the parameter of interest βi such that δi = 0 if βi = 0 and δi > 0 if βi 6= 0.
Therefore, the Wald test statistics for all measured SNPs are regarded as reduced data that
are highly informative about the parameter of interest. We defined the true association

6
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Table 1: Model types of Section 2.2 and the specific models defined in Section 2.3.
Parametric Semiparametric
Mixture
PMM
SMM
Nonmixture PNM
N/A
indicator
ai =



 0 if δi = 0

(2)


 1 if δi > 0
to indicate whether or not the ith SNP is associated with a certain disease. Then the
proportion of the non-associated SNPs is p0 = # (ai = 0) /N , where # (ai = 0) is the
number of truly non-associated SNPs.

2.2

Types of models for estimation

In order to evaluate the strength of evidence and to estimate ai and p0 , the assumed true
model of Section 2.1 must be simplified. The main simplifying assumption is that any
observed Wald test statistic t for the disease-associated SNPs was sampled from the same
distribution. These simplified models, to be specified in Section 2.3, differ in whether
they are parametric models and in whether they are mixture models. Table 1 shows the
categorization of each model.

2.2.1

Parmetric versus semiparametric

For the two parametric models, we assume that the Wald test statistics for the diseaseassociated SNPs are generated from a noncentral χ2 distribution of 1 degree of freedom and
of a single noncentrality parameter δi = δalt for all i corresponding to disease-associated
SNPs. Bukszár et al. (2009) also assigned a single noncentrality parameter value to all SNPs
not associated with disease. Similarly, for microarray data, a three-component mixture

7
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model performs as well as more complex models according to Muralidharan (2010) with
the three components corresponding to null, negative and positive groups. Since the Wald
test statistics of Section 2.1 can never be negative, the three components in that microarray
model are analogous to the two components of this paper. The two parametric models can
also work well with test statistics from other distributions, e.g., the Student t family of
distributions used in microarray studies.
For the semiparametric model, the density function of the transformed Wald test statistics for the disease-associated SNPs is estimated nonparametrically. Without modifying
the method of estimation, we will use a χ2 distribution because our test statistics are
χ2 -distributed under the null hypothesis.

2.2.2

Mixture versus nonmixture

In the two mixture models, for the ith SNP, we use the symbol Ai to represent a random
association indicator, and we denote the prior probability that the ith SNP is not associated
with disease by π0 = P (Ai = 0). In the nonmixture model, as in the model assumed to be
true (Section 2.1), we use ai to represent the fixed association indicator, with ai = 1 if the
ith SNP is associated with a certain disease and with ai = 0 if it is not.

2.3

Models for estimation

The following three models will be used to estimate each ai of the true model specified in
Section 2.1. For economy of notation, the same symbol b
ai will denote the estimator of ai
for each of the estimating models.

2.3.1

Semiparametric mixture model (SMM)

For any observed Wald test statistic ti , zi = Φ−1 (G0 (ti )) is called the z-transformed
statistic, where Φ is the standard normal cumulative distribution function (cdf) and G0
8
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is the cdf of the central χ2 distribution of 1 degree of freedom. The observed Wald test
statistics t1 , . . . , tN are transformed into z1 , . . . , zN , and for the ith SNP, the density is a
mixture of the form
f (zi ) = π0 f0 (zi ) + (1 − π0 ) f1 (zi ) ,

(3)

where f0 is the density function of z for the non-associated SNPs, and f1 is that for the
disease-associated SNPs.
For the ith SNP, LFDR is the posterior probability

LFDRSMM (zi ) = P (Ai = 0|zi ) =

π0 f0 (zi )
,
f (zi )

(4)

which may be interpreted as a level of certainty in the hypothesis that the ith SNP is not
associated with disease (Ai = 0) and is associated with disease (Ai = 1). The density
function f0 is assumed to be standard normal, N (0, 1), called the theoretical null. Another approach is to estimate the null density (Efron, 2004, 2007a), but such estimation
unnecessarily increases the variance of the estimates of interest for the application of this
paper, as explained in Section 3. Following Efron (2004), we use a nonparametric method
to estimate f by fb and an empirical Bayes method to estimate π0 by π
b0 , and then compute
\ SMM (zi ) by substituting π
LFDR
b0 and fb into π0 and f in equation (4). The natural estimate


\ SMM (zi )
b0 ). We choose the estimator b
ai = 1 − LFDR
of f1 is then fb1 = fb − π
b0 f0 / (1 − π
to estimate ai of equation (2).
2.3.2

Parametric mixture model (PMM)

For the ith SNP, the density g (ti ) is defined by replacing f (zi ), f0 (zi ) and f1 (zi ) in
equation (3) with g (ti ), g0 (ti ) and gδalt (ti ). The log-likelihood of PMM with unknown
parameters π0 and δalt is thus

9
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log L (π0 , δalt ) =

N
X

log [π0 g0 (ti ) + (1 − π0 ) gδalt (ti )] ,

i=1

which is maximized numerically by the maximum likelihood estimates π
b0 and δbalt . The
gδbalt is an estimate of gδalt , and gb is the corresponding estimate of g. For the ith SNP,
\ PMM (ti ) estimates ai , where LFDR
\ PMM (ti ) = π
b
ai = 1− LFDR
b0 g0 (ti ) /b
g (ti ) is the estimator
of the LFDR.
Under the two parametric models, the log-likelihood ratio for the ith SNP,

∆i (ti ) = log2 (gδalt (ti ) /g0 (ti ))

(5)

is regarded as the ideal information for discrimination favoring the hypothesis of association (δi = δalt ) over that of non-association (δi = 0) (Kullback, 1968). The information
is called ideal because the δalt is unknown. Here we chose the binary logarithm (log2 ) to
facilitate interpretation. Following the evidence levels of that Bickel (2010c) considered,
the discrimination information indicates strong evidence (∆i (ti ) > 3), very strong evidence (∆i (ti ) > 5) and overwhelming evidence (∆i (ti ) > 7); see Royall (1997) for slightly
different names of the first two grades. Negative discrimination information, ∆i (ti ) < 0,
indicates evidence in favor of non-association, which cannot be integrated by p-values since
they can only quantify the evidence against non-association (Wei et al., 2010).
For the ith SNP, the approximate information for discrimination is obtained by substituting gδbalt (ti ) into gδalt (ti ) in equation (5). That approximation also closely approximates
an MDL-based information for discrimination (Bickel, 2010b).

10
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2.3.3

Parametric nonmixture model (PNM)

Under the assumption that for the ith SNP, the observed Wald test statistic ti is sampled
from g0 (ti ) if ai = 0 or from gδalt (ti ) if ai = 1, the density of ti is

g (ti , δalt , ai ) = ai g0 (ti ) + (1 − ai ) gδalt (ti ) ,

(6)

and the log likelihood with the unknown parameters δalt and a1 , . . . , aN is

log L (δalt , a1,... , aN ) =

N
X

log (g (ti , δalt , ai )) .

(7)

i=1

The maximum likelihood estimates of the parameters a1 , . . . , aN are computed by substituting
b
anaive
=
i



 0 ge (ti ) 6 g0 (ti )
δalt

,

(8)


 1 ge (ti ) > g0 (ti )
δalt

into ai in (7), where δealt is the value of δalt that maximizes the likelihood defined by equation
and δealt
(7). The estimated density functions ge and gδealt are obtained by substituting b
anaive
i
for ai and δalt in equation (6).
in equation (8) is a naive
For the ith SNP, the maximum likelihood estimator b
anaive
i
estimator for ai in that the decisions based on b
anaive
do not perform well due to its binary nai

ture. We use another estimator of ai , b
ai = 1− pb0 g0 (ti ) /e
gi (ti ), where pb0 = # b
anaive
= 0 /N
i
is an estimator of p0 (Bickel, 2010b).
For the ith SNP, the approximate information for discrimination is computed by substituting gδealt (ti ) into gδalt (ti ) in equation (5) (Bickel, 2010b).

11
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3

Application

The Coronary artery disease (CAD) data from Wellcome Trust Case Control Consortium
(2007) included 490,032 SNPs genotyped for 1988 cases and 3004 combined controls on
22 autochromosomes. We excluded SNPs with 10% missing genotypes, with minor allele
frequencies <5% and with p-values smaller than 0.05 from a Hardy-Weinberg equilibrium
exact test (Purcell et al., 2007). We also excluded the samples genotyped for less than 95%
of the SNPs. A total of N = 335,169 SNPs and 4934 samples (1947 cases, 2987 controls)
passed those quality control filters and were used in the following statistical analysis.
We computed the Wald test statistics for all N SNPs. In order to implement SMM,
we transformed the observed Wald test statistics into z-values. Since the central region
of the histogram of the z-values matches N (0, 1) very well, f0 is considered to be the
theoretical null. For PMM and PNM, the observed statistics were used to estimate the
model parameters. These estimates are shown in Table 2. The estimates of p0 under SMM
and PMM were denoted by π
b0 in Section 2.3, and SMM does not estimate δalt since instead
estimates f1 using the nonparametric method mentioned in Section 2.
We now introduce some additional notation to compare the three models with respect
to the CAD data under the assumed true model of Section 2.1, in which the Wald test
statistic for each disease-associated SNP is sampled from a noncentral χ2 distribution of
1 degree of freedom and of a potentially different noncentrality parameter value. The
average probability density function of the Wald test statistics for all disease-associated
SNPs, represented by f 1 , is defined as the mean of the probability density function of each
of its statistics. The estimated f 1 under SMM is equal to fb1 . For the two parametric
models, f 1 was estimated by gδbalt under PMM and by gδealt under PNM. In Figure 1, the
solid line is the estimated f1 under SMM, where the z-values are the transformed Wald
test statistics from the CAD data. For PMM and PNM, we simulated 500,000 Wald test

12
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Table 2: The estimation of parameters p0 and δalt in SMM, PMM and PNM in the CAD
data.
Models
SMM
PMM
PNM

Estimated p0
0.98
0.90
0.77

Estimated δalt
N/A
1.01
3.11

Table 3: The number of SNPs with evidence in favor of non-association (the negative
approximate information for discrimination) and with very strong evidence (approximate
information for discrimination larger than 5) and overwhelming evidence (approximate
information for discrimination larger than 7) in favor of association in the CAD data.
Negative Very strong
PMM 234,411
35
PNM 259,343
779

Overwhelming
19
82

statistics t from gδbalt and gδealt respectively, where the values of δbalt and δealt are from Table 2.
Then we transformed the t values into z values and to numerically approximate each density
function of z values. All three estimated density functions in Figure 1 were normalized
into the interval between 0 and 1.
The dark grey horizontal line illustrates the full width at half maximum (FWHM) for
the estimated f 1 under three models. Since there is more than one noncentrality parameter
value under the true model, f 1 is wider than the probability density function of each of its
SNPs. However, as seen in Figure 1, the FWHM for the SMM-estimated density is much
smaller than those of the other two estimated densities, each of which is in turn narrower
than f 1 .
Figure 2 displays the approximate discrimination information (Section 2.3) for all
measured SNPs, where the estimated odds ratio for the ith SNP is eβi . Table 3 reports the
b

numbers of SNPs with very strong or overwhelming evidence in favor of association and of
those with evidence in favor of non-association.

13
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0.8
0.4
0.0

estimated density

SMM
PMM
PNM

−10

−5

0

5

z−transformed Wald test statistic

Figure 1: The estimated density functions of the z-transformed Wald test statistics for the
disease-associated SNPs in the CAD data under three models.

Figure 2: The binary logarithm (log2 ) of the likelihood ratio versus the estimated odds
ratio for all measured SNPs in the CAD data under PMM (black) and PNM (grey).
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4

Simulation studies

The aim of the following simulation studies is to compare the performances of the estimators
under the three models of Section 2. First, we used the Kullback-Leibler divergence to
compare the deviations between the true distribution and the estimated distribution for
the disease-associated SNPs in the two parametric models (PMM and PNM). Second, we
compared the abilities of all three models to estimate p0 and ai .
All simulations were performed under the assumed true model of Section 2.1. According
to equation (1), each δi depends on the logarithm of the odds ratio, and SNPs with different
values of the odds ratio do not necessarily have the same value of δi . The simulation studies
are divided into two sets, one with multiple values of δalt and the other with a single value
of δalt for each study. In the former set, we assume that the observed Wald test statistics for
the disease-associated SNPs between disease-associated genes are generated from different
distributions with different values of δalt (Section 4.1). In the latter set, the observed Wald
test statistics for all disease-associated SNPs are sampled from the same distribution with
a single value of δalt (Section 4.2). In both sets, we assume that the observed Wald test
statistics for non-associated SNPs are from the same distribution with δi = 0. Bukszár
et al. (2009) similarly simulated test statistics but used different estimators and different
measures of performances than those employed herein.

4.1

Multiple values of δalt per study

The data were simulated as follows. There are 2000 effect-size groups affecting a certain
disease, and the number of SNPs in each effect-size group is evenly allocated. We performed 12 simulation studies, each with a different value of p0 and with the number of
the SNPs per effect-size group equal to one of the two integers closest to (1 − p0 )N/2000,
where in each simulation study, N is equal to 335,169, the total number of the mea-

15
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sured SNPs in Section 3.

For each of the 2000 disease-associated effect-size groups,

a noncentrality parameter δj > 0 was assigned. For the first two effect-size groups,
δ1 = δbalt = 1.01 and δ2 = δealt = 3.11, numbers that also appear in Table 2, whereas
for each j = 3, . . . , 2000, δj was generated from the uniform distribution between 0.5 and
5.
In each simulation study, we randomly generated 50 data sets, each corresponding to
an artificial case-control study. For each data set, we used the true model of Section 2 to
simulate the Wald test statistics, where the Wald test statistics for the SNPs within the jth
effect-size group associated with disease were sampled from the noncentral χ2 distribution
of 1 degree of freedom and of a noncentrality parameter δj , and the Wald test statistics
for the other non-associated SNPs were sampled from the noncentral χ2 distribution of 1
degree of freedom and of the noncentrality parameter equal to 0.
The Kullback-Leibler (KL) divergence is the expected difference between the ideal information for discrimination and the approximate information for discrimination defined
in Section 2.3.2, e.g., for the ith SNP,
i
h
i

h
b i (ti ) ,
KLi = E log2 gδalt (ti ) /gδbalt (ti ) = E ∆i (ti ) − ∆


b i (ti ) = log2 gb (ti ) /g0 (ti ) is the approximate information for discrimination
where ∆
δalt
under PMM. Here, gδbalt is fixed, and the expectation value is over Ti , which is distributed
according to gδalt . This KL divergence measures the performance of approximating the
ideal information for discrimination. The left panel of Figure 3 displays the numerically
approximated KL divergence for each simulation study averaged over all 50 data sets and
over all the disease-associated SNPs.
The bias for each estimator of p0 is E[b
p0 − p0 ]. The left panel of Figure 4 shows the bias
estimated by averaging pb0 − p0 over all 50 data sets. The estimated standard deviation of
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pb0 in each simulation study is <0.001% for all three models.
For the ith SNP, the frequentist risk for b
ai is R (ai , b
ai )= E[l (ai , b
ai )], the expected loss,
where b
ai is the estimate of ai defined for each model in Section 2.3 and l (ai , b
ai ) is the loss
of b
ai . In this paper, we consider the most widely used loss functions used to evaluate the
performance of probability assessments (Bernardo and Smith, 1994), namely the quadratic
loss l (ai , b
ai ) = (b
ai − ai )2 , and the logarithmic loss


 − log (1 − b
ai ) ai = 0
2
l (ai , b
ai ) =
.


− log2 b
ai
ai = 1
The expected quadratic loss and the expected logarithmic loss are called the mean square
error (MSE) and the logarithmic risk, respectively. In Figure 5, the infinite logarithmic
risk under SMM is due to the infinite logarithmic risk for the disease-associated SNPs since
\ SMM (zi ) is equal to
we have infinite loss for the disease-associated SNPs whenever LFDR
100%. In the Bayesian interpretation, this would mean absolute certainty that a particular
SNP is not associated with disease even though it is associated with disease (cf. Bickel,
2010a).
In the simulation studies above, we assumed for simplicity that there are 2000 effect-size
groups associated with disease and the SNPs within a effect-size group are independent. In
order to investigate whether the results are sensitive to the number of the disease-associated
effect-size groups and to the correlation between SNPs within a effect-size group, we also
performed additional simulation studies as before except that the number of the diseaseassociated effect-size group varied between 10 and 4000. For each of the disease-associated
groups, we considered the extreme case that the SNPs within a effect-size group have the
same Wald test statistics regarding the disease-associated group as a haplotype. The results
are not shown here since they do not affect the performance of the estimators relative to
each other.
17
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Figure 3: Left panel: the mean Kullback–Leibler divergence between gδalt and its estimator
versus p0 for two true values of δalt equal to 1.01 (grey) and 3.11 (black) under PMM
(circles) and under PNM (triangles) when each simulation study has multiple values of δalt
(Section 4.1). Right panel: the mean Kullback–Leibler divergence between gδalt and its
estimator versus the true values of δalt under PMM (circles) and under PNM (triangles)
when each simulation study has a single value of δalt (Section 4.2).
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estimator for all three models. In both panels, the estimated bias of each estimator of
p0 is positive under SMM(”x”), positive under PMM (circles) and negative under PNM
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ai versus p0 when each simulation study has multiple
values of δalt (Section 4.1) under three models, SMM (”x”), PMM (circles) and PNM
(triangles). Left panel: the approximate mean square error (MSE) of b
ai versus p0 . Right
panel: the approximate logarithmic risk of b
ai versus p0 . Under SMM, the approximate
logarithmic risk of b
ai is infinite and is not displayed.
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of δalt (Section 4.2).

4.2

One value of δalt per study

In this set of simulation studies, the true value of p0 is fixed at 0.90, the PMM estimate
reported in Table 2. Since the total number of markers is N = 335,169, the number of
disease-associated SNPs is equal to 33,516. We performed 8 simulation studies, each with
a different value of δalt , ranging from 0.5 to 5. Similar to Section 4.1, we simulated 50
data sets for each simulation study, and the results were plotted versus the true values of
δalt instead of the true values of p0 in the right-hand panels of Figure 3 and 4. Figure 6
displays the approximate risk of b
ai versus δalt for each simulation study.
We also conducted the simulation studies with the true value of p0 fixed at 0.77, the
PNM estimate (Table 2). The results are not displayed here since the relative performances
of the estimators associated with the three models are the same as that in the case of p0
fixed at 0.90.

5

Discussion

As observed in Section 3, the SMM estimate of f1 is much narrower than the true f 1 , which
indicates that using the nonparametric method to estimate the density function for the
disease-associated SNPs led to overfitting the CAD data. Such problems in estimating the
mean density function propagate to the estimates of the true association indicator ai and
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of the true null proportion p0 . While the parametric models may underfit the data, the
simulation studies of Section 4.1 demonstrated that they are robust against misspecification
in the form of multiple noncentrality parameters values.
Figure 4 indicates that SMM has a severe upward bias in estimating p0 , as previously
observed in microarray studies using similar semiparametric models (Pawitan et al., 2005).
As Pawitan et al. (2005) explained, that bias reflects the fact that nonparametric entity
estimators inadequately separate the features with small effect size from those with no
effect. The biased estimate of p0 will lead to a biased estimate of LFDR according to
equation (4). Using the biased estimate of LFDR in turn results in failing to detect
associations with SNPs of small odds ratios.
As a consequence of this bias, in both sets of simulation studies, the approximate
logarithmic risk for the disease-associated SNPs under SMM is infinite as a result of the
infinite loss for some of the disease-associated SNPs under SMM. Here, the infinite loss is
due to the value of the estimated LFDR equalling 100% for a specific disease-associated
SNP, which indicates that the LFDR estimator based on SMM does not have the Bayesian
posterior probability interpretation that popularized the LFDR.
Also due to this bias in estimating p0 , the investigator cannot interpret a high LFDR
estimate as evidence in favor of the null hypothesis. Both PMM and PNM can measure
the strength of evidence for the hypothesis of non-association (Table 3), but the LFDR
estimator based on SMM, similar to conventional p-values, cannot quantify the amount of
information in the data supporting non-association.
Among the two parametric models, PMM has substantially better performance for
estimating the true values of δalt and p0 and has slightly better performance for estimating
ai (Figures 3, 4, 5 and 6).
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